Oragenics Inc
OGEN0.791USD
-0.049-5.84%
Market hours （ET）Quotes delayed by 15 min
3.27MMarket Cap
LossP/E TTM
More Details of Oragenics Inc Company
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
Oragenics Inc Info
Ticker SymbolOGEN
Company nameOragenics Inc
IPO dateJul 09, 2003
CEOHuffman (Janet)
Number of employees3
Security typeOrdinary Share
Fiscal year-endJul 09
Address1990 Main Street
CitySARASOTA
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code34236
Phone18132867900
Websitehttps://www.oragenics.com/
Ticker SymbolOGEN
IPO dateJul 09, 2003
CEOHuffman (Janet)
Company Executives of Oragenics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick W. Telling, Ph.D.
Dr. Frederick W. Telling, Ph.D.
Independent Director
Independent Director
948.00
-210.00%
Mr. Robert C. Koski
Mr. Robert C. Koski
Independent Director
Independent Director
931.00
--
Mr. Charles L. Pope
Mr. Charles L. Pope
Executive Chairman of the Board
Executive Chairman of the Board
849.00
--
Ms. Janet Huffman
Ms. Janet Huffman
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
500.00
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Mr. Tirth T. Patel
Mr. Tirth T. Patel
Vice President
Vice President
--
--
Mr. John P. Gandolfo
Mr. John P. Gandolfo
Independent Director
Independent Director
--
--
Dr. James Kelly, M.D.
Dr. James Kelly, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. William (Frank) Peacock, M.D.
Dr. William (Frank) Peacock, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Ms. Natasha Giordano
Ms. Natasha Giordano
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick W. Telling, Ph.D.
Dr. Frederick W. Telling, Ph.D.
Independent Director
Independent Director
948.00
-210.00%
Mr. Robert C. Koski
Mr. Robert C. Koski
Independent Director
Independent Director
931.00
--
Mr. Charles L. Pope
Mr. Charles L. Pope
Executive Chairman of the Board
Executive Chairman of the Board
849.00
--
Ms. Janet Huffman
Ms. Janet Huffman
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
500.00
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Mr. Tirth T. Patel
Mr. Tirth T. Patel
Vice President
Vice President
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Feb 2
Updated: Mon, Feb 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sabby Management, LLC
9.90%
Five Narrow Lane LP
1.97%
Clear Street LLC
1.69%
DRW Securities, LLC
1.48%
Cassidy (Bruce A Sr)
0.28%
Other
84.67%
Shareholders
Shareholders
Proportion
Sabby Management, LLC
9.90%
Five Narrow Lane LP
1.97%
Clear Street LLC
1.69%
DRW Securities, LLC
1.48%
Cassidy (Bruce A Sr)
0.28%
Other
84.67%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
10.05%
Corporation
1.98%
Research Firm
1.70%
Investment Advisor
1.57%
Individual Investor
0.40%
Other
84.30%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
50
549.18K
13.18%
+437.32K
2025Q3
45
104.12K
2.50%
+81.57K
2025Q2
52
24.58K
2.99%
-32.18K
2025Q1
54
104.53K
39.81%
+67.24K
2024Q4
61
3.11M
25.46%
+2.05M
2024Q3
59
1.22M
18.08%
+226.05K
2024Q2
58
1.45M
24.58%
+674.78K
2024Q1
57
1.51M
26.60%
+861.00K
2023Q4
59
1.13M
28.10%
+795.74K
2023Q3
58
266.28K
10.68%
+19.84K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sabby Management, LLC
58.95K
1.41%
+58.95K
--
Sep 30, 2025
Five Narrow Lane LP
82.21K
1.97%
+82.21K
--
Jul 02, 2025
Clear Street LLC
70.62K
1.69%
+70.62K
--
Jun 30, 2025
DRW Securities, LLC
61.81K
1.48%
+61.81K
--
Sep 30, 2025
Cassidy (Bruce A Sr)
11.82K
0.28%
+3.00
+0.03%
Mar 21, 2025
UBS Financial Services, Inc.
271.00
0.01%
-1.62K
-85.68%
Sep 30, 2025
Telling (Frederick W)
948.00
0.02%
-210.00
-18.13%
Dec 12, 2025
Koski (Robert C)
931.00
0.02%
--
--
Mar 21, 2025
Dunton (Alan W)
854.00
0.02%
--
--
Mar 21, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
May 28, 2025
Merger
30→1
Dec 23, 2022
Merger
60→1
Dec 23, 2022
Merger
60→1
Dec 23, 2022
Merger
60→1
Dec 23, 2022
Merger
60→1
Date
Ex-dividend Date
Type
Ratio
May 28, 2025
Merger
30→1
Dec 23, 2022
Merger
60→1
Dec 23, 2022
Merger
60→1
Dec 23, 2022
Merger
60→1
Dec 23, 2022
Merger
60→1
